The present application provides activating antigen carriers (AACs) for treating HPV-associated cancers. AACs are derived from anucleate cells in which at least one antigen and an adjuvant have been delivered intracellularly. In some embodiments, the AAC is administered in combination with a checkpoint inhibitor such as a CTLA4 antagonist and/or a PD-1/PD-L1 agonist.

Provided herein are compositions and methods related to the multivirus-specific T cell immunotherapy.

Disclosed is an immunity inducer. The immunity inducer comprises virus like particles; the virus like particles comprise a virus-derived outer coat protein and an antigen-bound protein comprising an exogenous antigen; the outer coat protein constitutes an outer coat of the virus like particles, and the antigen-bound protein is comprised in the outer coat; and the virus like particles induce an immune effect of a living body on the antigen.

The present invention provides a novel vaccine for preventing and treating Merkel cell carcinoma. The present invention constructs a therapeutic vaccine based on a Merkel cell polyomavirus capsid protein VP1 by taking the Merkel cell polyomavirus capsid protein VP1 as an antigen, in combination with a TLR agonist. The present invention effectively solves the problem of prevention and treatment of the Merkel cell carcinoma and has great application value and application prospects.

The present disclosure provides for isolated and processed cell therapeutic compositions and Methods of using those compositions for the treatment of a patient undergoing a hematopoietic stem cell transplant (HSCT). In some embodiments, the disclosure provides for methods of making these cells by exposing the isolated T cell populations to one or more tumor antigens.

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Merkel Cell Polyomavirus (MCV) T antigen. Immunomodulatory methods and methods of inducing an immune response against MCV are disclosed. Method of treating infection by MCV and methods of treating or preventing Merkel Cell Carcinoma associated with MCV are disclosed. Modified consensus MCV T antigens are disclosed.

Provided herein are methods of rapidly expanding BKV-specific T cells using a peptide mixture and cytokines. Further provided herein are methods of treating polyomavirus-associated diseases by administering the BKV-specific T cells.

Provided herein are methods and compositions related to polyomavirus epitopes useful in the treatment of cancer or a polyomavirus infection.

We provide a polypeptide vaccine for treatment and prevention of cancer, particularly prevention of metastasis of cancer. Also provided are methods of treating or preventing cancer, and pharmaceutical compositions comprising the polypeptide vaccine.